The influenza
diagnostics market is expected to reach USD 3.3 billion by 2024,
according to a new report by Grand View Research, Inc. Influenza, or "the
flu," is an infectious disease and affects the upper respiratory tract in
humans. The disease is common in children and elderly population (aged 65 years
and above). The disease has a huge impact on public health. Influenza A virus
poses a greater risk as compared to the influenza B virus. The B virus is
responsible for 20% to 25% of infections globally. The growth in the influenza
diagnostic market is attributed to factors such as emergence of technologically
advanced diagnostic tests with shorter turnaround time; initiatives by
regulatory bodies, such as CDC’s seasonal influenza vaccination for prevention
and control of seasonal influenza; and the demand created for influenza
diagnosis in the flu season.
Rapid Influenza Diagnostic Tests (RIDTs) accounted for
the largest share in 2015. RIDTs are tests that deliver accurate results in
approximately 15 minutes. This factor deems them efficient, which has resulted
in the lucrative growth of this segment with the fastest CAGR. Reverse
transcription polymerase chain reaction (RT-PCR) holds the second highest
market share following RIDTs, and this can be attributed to the fact that it
provides detailed analytical results, sharper turnaround times, and high
throughput.
Hospitals held the highest market share in 2015, but
Point-of-Care Testing (POCT) is anticipated to overtake and lead the market in
the coming future, owing to the increasing usage of POCT because of its ease of
use and short turnaround times.
North America dominates the market, due to a high
focus of the government and healthcare bodies to control influenza.
Browse full research report on Influenza Diagnostics Market: www.grandviewresearch.com/industry-analysis/influenza-diagnostics-market
Further
Key Findings From the Study Suggest:
- North America is anticipated to dominate the global influenza
diagnostics market. The high adoption rates of in vitro diagnostics and
presence of technologically advanced medical devices is expected to drive
growth in the region.
- The Asia Pacific region is anticipated to be the fastest growing
region in the study period. This growth is attributed to factors such as
increasing initiatives by the countries to counter the incidence of the
disease. For instance, CDC reached a cooperative agreement with South-East
Asian Region to fund non research-related bilateral influenza as a measure
to respond to avian, seasonal, and pandemic influenza.
- The RIDT segment is expected to grow at a significant rate compared
to others and accounts for the largest share in 2015.
- This market comprises several local as well as global players. Some
of the major players of this vertical include Becton, Dickinson and
Company, Roche Diagnostics, Alere, Quidel Corporation, and Thermo Fisher
Scientific.
Browse more reports of this category
by Grand View Research: www.grandviewresearch.com/industry/clinical-diagnostics
Grand View Research has segmented the influenza
diagnostics market on the basis of test type, end use, and region:
Test
Type Outlook (Revenue, USD Million, 2013 - 2024)
- RIDTs
- RT-PCR
- Cell Culture
- Others
End-use
Outlook (Revenue, USD Million, 2013 - 2024)
- Hospital
- Point-of-Care
Testing
- Laboratories
Regional
Outlook (Revenue, USD Million, 2013 - 2024)
- North America
- U.S.
- Canada
- Europe
- Germany
- UK
- Asia Pacific
- China
- India
- Latin America
- Brazil
- Mexico
- MEA
- South Africa
- Saudi Arabia
About Grand View
Research
Grand View Research, Inc. is a U.S. based market
research and consulting company, registered in the State of California and
headquartered in San Francisco. The company provides syndicated research
reports, customized research reports, and consulting services. To help clients
make informed business decisions, we offer market intelligence studies ensuring
relevant and fact-based research across a range of industries, from technology
to chemicals, materials and healthcare.
For more information: www.grandviewresearch.com
No comments:
Post a Comment